A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

ClinicalTrials.gov Identifier: NCT01311050

Recruitment Status: Unknown
Verified December 2011 by King Faisal Specialist Hospital & Research Center.
Recruitment status was: Recruiting
First Posted: March 9, 2011
Last Update Posted: December 13, 2011

Sponsor:
King Faisal Specialist Hospital & Research Center

Information provided by (Responsible Party):
King Faisal Specialist Hospital & Research Center

Study Description

Brief Summary:
A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
**Condition or disease**  
Metastatic Colorectal Cancer

**Intervention/treatment**  
Drug: Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab

**Detailed Description:**
A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

**Study Design**

**Study Type**: Observational

**Estimated Enrollment**: 46 participants

**Observational Model**: Case-Control

**Time Perspective**: Prospective

**Official Title**:
A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

**Study Start Date**:
January 2009

**Resource links provided by the National Library of Medicine**
Drug Information available for: Oxaliplatin, Irinotecan, Irinotecan hydrochloride, Capecitabine, Bevacizumab

**U.S. FDA Resources**

**Groups and Cohorts**

**Intervention Details**:
- Drug: Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab
  - Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:
14 Years to 85 Years (Child, Adult, Older Adult)

Sexes Eligible for Study:
All

Accepts Healthy Volunteers:
No

Sampling Method:
Non-Probability Sample

Study Population
Metastatic Colorectal Cancer

Criteria

Inclusion Criteria:
- Patients with diagnosed Metastatic Colorectal Cancer

Exclusion Criteria:
- Patients with diagnosis other than Metastatic Colorectal Cancer

Contacts and Locations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): **NCT01311050**

**Contacts**

Contact: Shouki **Bazarbashi**, M.D.  +966-1-4423949

**Locations**

**Saudi Arabia**

Kfsh & Rc  Recruiting

Riyadh, Saudi Arabia

**Sponsors and Collaborators**

King Faisal Specialist Hospital & Research Center

**Investigators**

Principal Investigator:  Shouki **Bazarbashi**, M.D.  KFSH & RC

**More Information**

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):


**Responsible Party:**

King Faisal Specialist Hospital & Research Center

**ClinicalTrials.gov Identifier:**

[NCT01311050](https://clinicaltrials.gov/ct2/show/NCT01311050)  History of Changes

**Other Study ID Numbers:**

RAC# 2081-068

RAC# 2081-068